gastroparesis and glp 1 drugs GLP-1 Gastroparesis: Hidden Dangers Beyond C GLP-1 Gastroparesis Lawsuit: Stomach Paralysis

Glucagon activation higher energy expenditure & fat oxidation

Lrke Smidt Gasbjerg, University of Copenhagen, Denmark Updates Copyright 2022 Gallwitz

To overcome this assessment, pharmaceutical companies are instead targeting obesity-related co-morbidities, such as cardiovascular disease, chronic kidney disease and obstructive sleep apnoea, for which reimbursement is more likely

Efficacy and safety of liraglutide monotherapy compared with metformin in Japanese overweight/obese patients with type 2 diabetes

doi: 10.2967/jnumed.106.038679

These drugs mimic a natural hormone to regulate appetite, but safety depends on individual health history and managing potential side effects like nausea